Mirati Therapeutics price target raised to $65 from $57 at Oppenheimer. Oppenheimer analyst Leah Rush raised her price target for Mirati Therapeutics to $65 from $57 after the company announced that it has dosed the first patient in a phase I/II study of MRTX849, in line with prior guidance. The analyst notes that the initiation of this study, along with recent encouraging data from the first preclinical results for this KRAS G12C inhibitor, supports her outlook. She reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.